{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-029731","form_type":"8-K","ticker":"STRO","cik":"0001382101","company_name":"SUTRO BIOPHARMA, INC.","filed_at":"2023-06-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.652211+00:00","generated_at":"2026-06-13T16:56:21.157345+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Sutro Biopharma sells 4% royalty on Vaxcyte products to Blackstone for $140M upfront","bullets":["Sold 4% royalty interest in Vaxcyte's future net sales (including VAX-24) to Blackstone Life Sciences.","Received $140M upfront payment on June 23, 2023 from Blackstone.","Eligible for up to $250M additional payments upon achieving return thresholds.","Retains rights to discover and develop vaccines for non-infectious diseases, including cancer.","Agreed to covenants on amending, assigning, and terminating the License Agreement with Vaxcyte."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-029731","json":"https://secwatch.observer/filing/0000950170-23-029731.json","markdown":"https://secwatch.observer/filing/0000950170-23-029731.md","text":"https://secwatch.observer/filing/0000950170-23-029731.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1382101/000095017023029731/0000950170-23-029731-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1382101/000095017023029731/stro-20230621.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T16:56:21.157345+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c4b2e99ee2f9c210b684c34be08ddfd3bd20f535","claim":"SUTRO BIOPHARMA, INC. entered into Purchase Agreement with affiliate of Blackstone Life Sciences valued at $140.0 million (effective 2023-06-21).","evidence_excerpt":"On June 21, 2023, Sutro Biopharma, Inc. (the “ Company ”) entered into a purchase and sale agreement (the “ Purchase Agreement ”) with an affiliate of Blackstone Life Sciences (“ Blackstone ”, and together with the Company, the “ Parties ”), pursuant to which the Company sold to Blackstone its 4% royalty, or revenue interest, in the potential future net sales of Vaxcyte Inc.’s (“ Vaxcyte ”) products, including VAX-24 (the “ Purchased Interest ”) under that certain Amended and Restated SutroVax Agreement, dated October 12, 2015, by and between the Company and Vaxcyte, as amended (the “ License Agreement ”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1382101/000095017023029731/0000950170-23-029731-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"asset purchase"},{"label":"Counterparty","value":"affiliate of Blackstone Life Sciences"},{"label":"Value","value":"$140.0 million"},{"label":"Effective","value":"2023-06-21"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}